Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.71 - $17.82
Previous CloseN/A
Volume344.54K
Average Volume (3M)1.85M
Market Cap
$480.61M
Enterprise Value$687.57M
Total Cash (Recent Filing)$61.74M
Total Debt (Recent Filing)$154.91M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 11, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding64,685,420
10 Day Avg. Volume1,383,830
30 Day Avg. Volume1,846,846
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue2.48
Enterprise Value/Gross Profit3.71
Enterprise Value/Ebitda-18.82
Forecast
1Y Price Target
$19.40Price Target Upside153.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe company plans to conduct strategic cost structure optimization to save at least $25M in operating expense for 2025 and expects to achieve meaningful profitability in 4Q25 and annual profitability beginning in 2026.
Product LaunchThere is a positive outlook for the exciting new launch of a second product line with Evolysse.
Strategic ExpansionEvolus expanded into the injectable hyaluronic acid (HA) gel market with two capital efficient distribution agreements.
Bears Say
Consumer SentimentContinued tariff threats and negative macroeconomic factors are expected to weigh on consumer sentiment and aesthetics demand.
Earnings GuidanceThe company reset 2025 net revenue guidance to $295-$305M from previously guided $345-$355M, with the new guide representing 11%-15% growth, down from the prior guide's 30%-33% growth.
Market DemandDeteriorating demand for aesthetics caught up with Jeuveau, leading to lower purchase volumes.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $5.71 and its highest was $17.82 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $480.61M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Nov 11, 2025 which is in 74 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Aug 05, 2025. The company reported -$0.247 earnings per share for the quarter, missing the consensus estimate of -$0.099 by -$0.148.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is -0.15.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 64,685,420 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.247 in its last earnings report, missing expectations of -$0.099. Following the earnings report the stock price went down -28.507%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
Evolus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.40 (153.59% Upside)
$19.40 (153.59% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $889.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.15%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-2.13%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc. is a performance-based aesthetic company focused on delivering innovative, non-surgical aesthetic solutions to enhance beauty and confidence. The company primarily operates in the medical aesthetics sector and offers products designed to address the needs of consumers and healthcare providers. Evolus is known for its flagship product, Jeuveau, a botulinum toxin type A injectable treatment aimed at reducing the appearance of glabellar lines, commonly known as frown lines. The company focuses on providing advanced aesthetic technologies that cater to a growing market of consumers seeking non-invasive aesthetic treatments.
EOLS Company Deck
EOLS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call depicted both strong achievements, particularly with the successful launch of Evolysse and international expansion, and significant challenges, including decreased demand for Jeuveau and a challenging market environment. While there are optimistic signs for the future, such as expected improvements in demand and strategic cost optimizations, the immediate outlook is hindered by current market conditions.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$19.40
▲(153.59% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Tilray
―
Ownership Overview
3.11% Insiders
10.54% Mutual Funds
52.99% Other Institutional Investors
24.08% Public Companies and
Individual Investors